Monograph Title | Section | Source Publication | Page Number | Errata Post Date | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication Sort ascending | Description |
---|---|---|---|---|---|---|---|---|
CETYL ALCOHOL | IMPURITIES/Limit of Related Fatty Alcohols | USP39–NF34 | 7239 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Line 1 of Sample solution: Change 1 mg/mL of Cetyl Alcohol in ethanol to: Prepare 1.0 mg/mL of Cetyl Alcohol in ethanol, and heat the solution in a sealed container in a 50° water bath until cetyl alcohol is dissolved. Allow the solution to cool to room temperature, and mix well. |
METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER | IMPURITIES/Limit of Methacrylic Acid and Ethyl Acrylate | First Supplement to USP39–NF34 | Online | 25-Mar-2016 | 1-Apr-2016 | USP40–NF35 | USP40–NF35 | Line 5 of Standard solution: Change Mix 10.0 mL of this solution to: Mix 5.0 mL of this solution AND Line 7 of Standard solution: Change about 0.67 µg/mL to: about 0.5 µg/mL Line 4 of Sample solution: Change 10.0 mL of this solution to:… Read More |
LORAZEPAM INJECTION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP39–NF34 | 4620 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Line 3 of Lorazepam Related Compound B RS: Change C13H9ClNO to: C13H9Cl2NO |
RANITIDINE ORAL SOLUTION | USP Reference standards <11> | USP39–NF34 | 5671 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Line 2 of USP Ranitidine Related Compound C RS: Change N-[2-[[[5-[(Dimethylamino)methyl]-2-furanyl]methyl]sulfinyl]ethyl]-N-methyl-2-nitro-1,1-ethenediamine. to: N-{2-[({5-[(Dimethylamino)methyl]-2-furanyl}methyl)sulfinyl]ethyl}-N′-methyl-2-nitro-1,1-… Read More |
<1132> RESIDUAL HOST CELL PROTEIN MEASUREMENT IN BIOPHARMACEUTICALS | 4. HCP IMMUNOASSAY METHOD VALIDATION/4.3 Sample Linearity/Table 4 | Second Supplement to USP38–NF33 | 7647 | 25-Mar-2016 | 1-Apr-2016 | USP40–NF35 | USP40–NF35 | Product column: Change 10.00 (neat), 5.00, 2.50, 1.25, 0.63, 0.31, 0.16 to: 10.00 (neat), 5.00, 2.50, 1.25, 0.625, 0.3125, 0.15625 AND Sample 1/HCP ratio column: Change 4.9, 5.7, 4.8, 5.9, 5.0, 5.1, <6 to: 4.90, 5.70, 4.80, 5.92, 4.96, 5.12, <6 AND… Read More |
MYRISTYL ALCOHOL | ASSAY/Procedure | USP39–NF34 | 7413 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Line 1 of Standard solution: Change Prepare 1.0 mg/mL of USP Myristyl Alcohol RS in Internal standard solution, and heat the solution in a sealed container in a 50° water bath until myristyl alcohol is dissolved. Allow the solution to cool to room temperature, and mix well. to… Read More |
DIGOXIN | IMPURITIES/Related Glycosides/System suitability | Interim Revision Announcement (Official November 01, 2015) | Online | 25-Mar-2016 | 1-Apr-2016 | USP40–NF35 | USP40–NF35 | Line 2: Change Sample: System suitability solution to: Samples: System suitability solution and Standard solution AND Line 2 of Suitability requirements: Change Resolution: NLT 1.5 between the digoxin and lanatoside C peaks Relative… Read More |
LORAZEPAM ORAL CONCENTRATE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP39–NF34 | 4621 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Line 3 of Lorazepam Related Compound B RS: Change C13H9ClNO to: C13H9Cl2NO |
RANITIDINE TABLETS | USP Reference standards <11> | USP39–NF34 | 5672 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Line 2 of USP Ranitidine Related Compound C RS: Change N-[2-[[[5-[(Dimethylamino)methyl]-2-furanyl]methyl]sulfinyl]ethyl]-N-methyl-2-nitro-1,1-ethenediamine. to: N-{2-[({5-[(Dimethylamino)methyl]-2-furanyl}methyl)sulfinyl]ethyl}-N′-methyl-2-nitro-1,1-… Read More |
<661.1> PLASTIC MATERIALS OF CONSTRUCTION | SPECIFICATIONS/Polyethylene/Extractable Metals | USP39–NF34 | 493 | 25-Mar-2016 | 1-Apr-2016 | USP40–NF35 | USP40–NF35 | Line 1 of Zirconium: Change 1 µg/g. to: 0.1 µg/g. |
OLEYL ALCOHOL | ASSAY/Procedure | USP39–NF34 | 7424 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Line 1 of Standard solution: Change Prepare 1.0 mg/mL of USP Oleyl Alcohol RS in Internal standard solution, and heat the solution in a sealed container in a 50° water bath until oleyl alcohol is dissolved. Allow the solution to cool to room temperature, and mix well. to: 1.… Read More |
MEMANTINE HYDROCHLORIDE TABLETS | IMPURITIES/Organic Impurities | Revision Bulletin (Official October 01, 2015) | Online | 25-Mar-2016 | 1-Apr-2016 | USP40–NF35 | USP40–NF35 | Line 3 of Analysis: Change of USP Memantine Related Compound E RS or to: of memantine related compound E or AND In the variable definition list: Change rU = peak response of USP Memantine Related Compound E RS or any individual degradation product from… Read More |
LORAZEPAM TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards RS <11> | USP39–NF34 | 4622 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Line 3 of USP Lorazepam Related Compound B RS: Change C13H9ClNO to: C13H9Cl2NO |
RANITIDINE IN SODIUM CHLORIDE INJECTION | USP Reference standards <11> | USP39–NF34 | 5673 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Line 2 of USP Ranitidine Related Compound C RS: Change N-[2-[[[5-[(Dimethylamino)methyl]-2-furanyl]methyl]sulfinyl]ethyl]-N-methyl-2-nitro-1,1-ethenediamine. to: N-{2-[({5-[(Dimethylamino)methyl]-2-furanyl}methyl)sulfinyl]ethyl}-N′-methyl-2-nitro-1,1-… Read More |
<661.1> PLASTIC MATERIALS OF CONSTRUCTION | SPECIFICATIONS/Polyethylene Terephthalate and Polyethylene Terephthalate G/Extractable Metals | USP39–NF34 | 493 | 25-Mar-2016 | 1-Apr-2016 | USP40–NF35 | USP40–NF35 | Line 1 of Titanium: Change 0.1 µg/g. to: 1 µg/g. |
SODIUM CETOSTEARYL SULFATE | IMPURITIES/Limit of Sodium Chloride and Sodium Sulfate/Sodium sulfate/Titrimetric system | USP39–NF34 | 7518 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Line 1 of Endpoint detection: Change Potentiometric to: Visual |
<1724> SEMISOLID DRUG PRODUCTS—PERFORMANCE TESTS | IN VITRO PERFORMANCE TESTS | USP39–NF34 | 1869 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Line 7 of Application of Drug Release: Change The individual amounts of drug released from R is plotted versus time, to: The individual amounts of drug released from R are plotted versus the square root of time, |
METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution <711> | USP39–NF34 | 4766 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Line 3 of Test 3: Change Medium, Apparatus 1, Apparatus 2, and Analysis: to: Medium, Apparatus 1, and Apparatus 2: |
SAMARIUM Sm 153 LEXIDRONAM INJECTION | Other requirements | USP39–NF34 | 5791 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Line 1: Change Injections and Implanted Drug Products <1>; not subject to Container Content. to: Meets the requirements of Injections and Implanted Drug Products <1>; not subject to Container content. |
<661.1> PLASTIC MATERIALS OF CONSTRUCTION | TEST METHODS/Extractions/Table 3 | USP39–NF34 | 493 | 25-Mar-2016 | 1-Apr-2016 | USP40–NF35 | USP40–NF35 | Column 4 of S3 row: Change Extractable metals: Al, Sb, As, Ba, Cd, Co, Ge, Hg, Mn, Ni, Pb, Ti, V, and Zn to: Extractable metals: Al, As, Ba, Cd, Co, Hg, Mn, Ni, Pb, Ti, V, and Zn |
<800> HAZARDOUS DRUGS—HANDLING IN HEALTHCARE SETTINGS | 5. FACILITIES AND ENGINEERING CONTROLS/5.3 Compounding | First Supplement to USP39–NF34 | 7721 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | First bullet in second paragraph: Change • Be externally vented through high-efficiency particulate air (HEPA) filtration to: • Be externally vented |
REAGENTS, INDICATORS AND SOLUTIONS | REAGENTS/6. General Tests for Reagents/6.2 Amino Nitrogen Test in Reagents | USP39–NF34 | 2080 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | In the numerator of the equation: Change 2.8 to: 14 AND Add × f AND Line 10: Change where %LOD is the percentage of loss on drying. to: where f is the correction factor obtained in the standardization of 0.2 N sodium hydroxide and %LOD is the… Read More |
MYCOPHENOLATE SODIUM | ASSAY/Procedure | USP39–NF34 | 4965 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Line 3: Change Solvent A to: Solution A AND Line 5: Change Solvent B to: Solution B |
TETRACYCLINE HYDROCHLORIDE CAPSULES | ASSAY/Procedure | USP39–NF34 | 6082 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Line 6 of Sample solution: Change dilute with Diluent to volume. to: dilute with Solution A to volume. |
<661.1> PLASTIC MATERIALS OF CONSTRUCTION | TEST METHODS/Extractions/Table 3 | USP39–NF34 | 493 | 25-Mar-2016 | 1-Apr-2016 | USP40–NF35 | USP40–NF35 | Line 1 of footnote b: Change For nonplasticized polyethylene only. to: For polyethylene only. |
ALPRAZOLAM EXTENDED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution <711> | USP39–NF34 | 2389 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Variable definition list of second equation in Test 2/Analysis: Change VS = volume of the Sample solution withdrawn at each time point and replaced with Medium (mL) to: VS = volume of the Sample solution withdrawn at… Read More |
PAROXETINE EXTENDED-RELEASE TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | First Supplement to USP39–NF34 | 8121 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | USP Paroxetine Related Compound B RS: Add C19H21NO3 · HCl 347.84 |
IDARUBICIN HYDROCHLORIDE INJECTION | SPECIFIC TESTS/Constituted Solution | USP38–NF33 | 3834 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Delete the Constituted Solution test. |
PHENYTOIN SODIUM | USP Reference standards <11> | USP37–NF32 | 4289 | 27-Mar-2015 | 1-Apr-2015 | USP39–NF34 | USP39–NF34 | Line 3 of USP Phenytoin Related Compound A RS: Change C14H15NO2 to: C14H13NO2 |
NIACIN | IMPURITIES/Related Compounds | First Supplement to USP38–NF33 | 7447 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Row 14 of Column 1 of Table 2: Change Total impurities to: Total specified impurities |
BISMUTH SUBCARBONATE | IMPURITIES/Limit of Lead | USP38–NF33 | 2449 | 27-Mar-2015 | 1-Apr-2015 | USP39–NF34 | USP39–NF34 | Line 1 of Acceptance criteria: Change Meets the requirements to: NMT 0.002% |
REAGENTS | REAGENT SPECIFICATIONS/Ferric Sulfate | USP38–NF33 | 1841 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Line 1: Change [10028-22-5] to: [15244-10-7] |
LEVETIRACETAM | IMPURITIES/Organic Impurities | USP38–NF33 | 4060 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Line 2 of Procedure 2: Change Buffer, Solution A, Solution B, Mobile phase, System suitability solution, and Chromatographic system: to: Buffer, Solution A, Solution B, Mobile phase, System suitability solution, Chromatographic system, and System suitability… Read More |
RIVASTIGMINE TARTRATE CAPSULES | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP37–NF32 | 4616 | 27-Mar-2015 | 1-Apr-2015 | USP39–NF34 | USP39–NF34 | Line 2 of USP Rivastigmine Related Compound A RS: Change Di-p-toluoyl-D-(+)-tartaric acid monohydrate. C20H20O9 404.37 to: (+)-Di-(p-toluoyl)-D-tartaric acid. C20H18O8 386.35 |
VERAPAMIL HYDROCHLORIDE EXTENDED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution <711>/Test 7 | First Supplement to USP38–NF33 | 7478 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Line 6 of Analysis: Change 37 ± 0.5° at each time point. to: 37 ± 0.5°. AND Line of 40 of Analysis:Delete the equation Result5 = ({C5 × [V − (4 × Vs)]} + [(C4 + C3 + C2… Read More |
CISATRACURIUM BESYLATE INJECTION | ASSAY/Procedure | USP38–NF33 | 2830 | 27-Mar-2015 | 1-Apr-2015 | USP39–NF34 | USP39–NF34 | Line 11 of Analysis: Change CS = concentration of USP Cisatracurium Besylate RS in the Standard solution to: CS = concentration of USP Cisatracurium Besylate RS in the Standard solution (mg/mL) |
ALUMINUM CHLOROHYDRATE | CHEMICAL INFORMATION | USP38–NF33 | 2130 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Line 8: Change Dihydrate [12042-91-0].Anhydrous [1327-41-9]. to: Dihydrate [12359-72-7].Anhydrous [12042-91-0]. |
LEVODOPA CAPSULES | IMPURITIES/Organic Impurities | USP38–NF33 | 4078 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Line 2 of Spray reagent: Change (10 mg/mL) to: (100 mg/mL) |
WITCH HAZEL | Limit of tannins | USP37–NF32 | 5177 | 27-Mar-2015 | 1-Apr-2015 | USP39–NF34 | USP39–NF34 | Line 3 of Chromatographic system: Change 5.0-mm × 15-cm to: 4.6-mm × 15-cm |
SODIUM CHLORIDE | IMPURITIES/Limit of Phosphates | Harmonization (Official December 01, 2015) | Online | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Line 2 of Analysis: Change add 4 mL of sulfomolybdic acid TS, to: add 4 mL of Sulfomolybdic acid solution, |
CLARITHROMYCIN TABLETS | IMPURITIES/Organic Impurities/Chromatographic system | USP38–NF33 | 2850 | 27-Mar-2015 | 1-Apr-2015 | USP39–NF34 | USP39–NF34 | Line 1 of Column: Change 4.6-mm × 10-cm; 3-µm packing L1 to: 4.6-mm × 10-cm; 3.5-µm packing L1 |
AZATHIOPRINE | ASSAY/Procedure | USP38–NF33 | 2334 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Line 1 of Standard stock solution: Change 0.1 mg/mL of USP Azathioprine RS prepared as follows. to: 0.5 mg/mL of USP Azathioprine RS prepared as follows. |
METHYLPHENIDATE HYDROCHLORIDE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP38–NF33 | 4345 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Line 3 of USP Methylphenidate Related Compound A RS: Change 255.75 to: 255.74 |
ASPARTAME | ASSAY/Procedure | USP37–NF32 | 5857 | 27-Mar-2015 | 1-Apr-2015 | USP39–NF34 | USP39–NF34 | Line 3 of Analysis: Change crystal violet to: crystal violet TS |
TELMISARTAN TABLETS | ASSAY/Procedure | Revision Bulletin (Official December 01, 2014) | Online | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Line 2 of Standard solution: Change of USP Telmisartan Related Compound A RS in Mobile phase. to: of USP Telmisartan Related Compound A RS in Mobile phase from the Standard stock solution. |
COSYNTROPIN | IDENTIFICATION/B. Amino Acid Analysis | USP38–NF33 | 2958 | 27-Mar-2015 | 1-Apr-2015 | USP39–NF34 | USP39–NF34 | Line 8 of Sample hydrolysate preparation: Change hydrochloride to: hydrochloric acid |
BENZOYL PEROXIDE GEL | IMPURITIES/Organic Impurities | USP38–NF33 | 2399 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Line 18 of Standard solution D: Change hydrous benzoyl peroxide (C14H10O4). to: anhydrous benzoyl peroxide (C14H10O4). |
METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution <711>/Test 2 | USP38–NF33 | 4348 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Line 3 of Apparatus 7: Change coil sample holder (Figure 4d). to: spring sample holder (Figure 5d). |
PURIFIED BENTONITE | IDENTIFICATION/A. X-Ray Diffraction <941> | USP37–NF32 | 5862 | 27-Mar-2015 | 1-Apr-2015 | USP39–NF34 | USP39–NF34 | Line 4 of Acceptance criteria: Change from the pattern of Sample B is 1.492 and 1.504 Å. to: from the pattern of Sample B is between 1.492 and 1.504 Å. |
TELMISARTAN TABLETS | IDENTIFICATION/A. Ultraviolet Absorption <197U> | Revision Bulletin (Official December 01, 2014) | Online | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Line 3: Change as obtained in the test for Dissolution. to: as obtained in the test for Dissolution, Test 1. |